A new trading day began on Friday, with Pyxis Oncology Inc (NASDAQ: PYXS) stock price down -5.88% from the previous day of trading, before settling in for the closing price of $1.36. PYXS’s price has ranged from $1.23 to $6.85 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged 40.99%. With a float of $42.25 million, this company’s outstanding shares have now reached $59.45 million.
In an organization with 50 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 84.98%, operating margin of -343.24%, and the pretax margin is -293.15%.
Pyxis Oncology Inc (PYXS) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Pyxis Oncology Inc is 28.95%, while institutional ownership is 40.70%. The most recent insider transaction that took place on Nov 26 ’24, was worth 174,364. In this transaction CFO & COO of this company bought 88,850 shares at a rate of $1.96, taking the stock ownership to the 1,199,143 shares.
Pyxis Oncology Inc (PYXS) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 40.99% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 12.25% during the next five years compared to -118.72% drop over the previous five years of trading.
Pyxis Oncology Inc (NASDAQ: PYXS) Trading Performance Indicators
Here are Pyxis Oncology Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 7.33. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.71.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.05, a number that is poised to hit -0.32 in the next quarter and is forecasted to reach -1.30 in one year’s time.
Technical Analysis of Pyxis Oncology Inc (PYXS)
Let’s dig in a bit further. During the last 5-days, its volume was 0.61 million. That was better than the volume of 0.6 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 38.61%. Additionally, its Average True Range was 0.10.
During the past 100 days, Pyxis Oncology Inc’s (PYXS) raw stochastic average was set at 1.20%, which indicates a significant decrease from 15.15% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 45.11% in the past 14 days, which was lower than the 116.59% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.5350, while its 200-day Moving Average is $3.0232. However, in the short run, Pyxis Oncology Inc’s stock first resistance to watch stands at $1.3467. Second resistance stands at $1.4133. The third major resistance level sits at $1.4567. If the price goes on to break the first support level at $1.2367, it is likely to go to the next support level at $1.1933. Assuming the price breaks the second support level, the third support level stands at $1.1267.
Pyxis Oncology Inc (NASDAQ: PYXS) Key Stats
With a market capitalization of 76.12 million, the company has a total of 59,466K Shares Outstanding. Currently, annual sales are 0 K while annual income is -73,790 K. The company’s previous quarter sales were 0 K while its latest quarter income was -17,300 K.
